Covista Inc. filings document current reports on operating results, academic performance, investor communications and strategic progress for its healthcare education portfolio. Recent Form 8-K records furnish quarterly results releases, enrollment metrics, revenue and earnings measures, fiscal guidance, share repurchase activity, debt refinancing references and institutional updates for Chamberlain and Walden.
The company's Regulation FD disclosures also include investor newsletters describing milestones, partnerships, workforce-related initiatives and operational progress. Covista's filing record identifies public-company disclosure themes tied to results of operations, capital allocation, governance signatories, cautionary forward-looking statements and the company's current identity as a NYSE-listed healthcare educator.
Covista Inc. director Leslie Storms received an award of 259 restricted stock units on October 15, 2026. Each unit represents a right to receive one share of common stock. The award was a prorated portion of her equity grant amount, based on the number of days between August 17, 2026 and the Annual Meeting date, divided by the $127.24 closing price of CVSA common stock on October 15, 2026. The units vest in full on November 12, 2026, subject to her continued service on the Board through that date.
Covista Inc. CHRO Sara Hill had 1,322 common shares withheld on October 15, 2026, at $127.24 per share to satisfy tax withholding obligations upon vesting of previously awarded restricted stock units. She directly held 8,954 common shares following the transaction. No Rule 10b5-1 plan is reported.
Covista Inc. (CVSA) director Emily C. Chiu received an award of 259 restricted stock units on October 15, 2026. Each unit represents a right to receive one share of common stock. The award count used the $127.24 closing price of CVSA common stock on that date in calculating her prorated equity grant. The units will vest in full on November 12, 2026, subject to her continued service on the Board through that date. Her reported balance following the award was 259 units.
Goldman Sachs & Co. LLC submitted a notice on behalf of Covista Inc. director Stephen Beard covering a proposed sale of 4,667 common shares, with an aggregate market value of $603,816.46 and an approximate sale date of October 9, 2026. The shares are to be sold from the Stephen Wayne Beard Trust u/a/d September 3, 2015; the trust's trustee is Stephen W. Beard Jr.
The sale is connected with a plan dated December 10, 2025, intended to comply with Rule 10b5-1(c). The shares were acquired as compensation through restricted stock units on September 8, 2025. The trust reported sales during the preceding three months of 5,291 shares on July 13, 2026, 3,545 shares on August 11, 2026, and 3,639 shares on October 8, 2026.
Covista Inc. Chairman & CEO Stephen W. Beard sold 3,639 shares on October 8, 2026, at a weighted average price of $130.3690 per share, and 4,667 shares on October 9, 2026, at a weighted average price of $130.7690 per share. Both sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025. The reported footnotes state the shares came from holdings above Covista’s Stock Ownership and Holding Requirements and were sold in pre-scheduled increments.
Covista Inc. director Stephen Beard reported a proposed sale of 3,639 common shares, with an aggregate market value of $474,125.31 and an approximate sale date of October 8, 2026. Goldman Sachs & Co. LLC is listed as the broker, and NYSE as the exchange. The shares are to be sold from the Stephen Wayne Beard Trust; the related trust entry names Stephen W. Beard Jr. as trustee. The sale is connected to a selling plan dated December 10, 2025, intended to comply with Rule 10b5-1(c). The shares were acquired as compensation through restricted stock units on September 8, 2025. In the past three months, the trust's reported sales were 5,291 shares for $702,399.3 on July 13, 2026, and 3,545 shares for $462,073.73 on August 11, 2026.
Covista Inc. is asking shareholders to elect 11 director nominees and vote on auditor ratification, executive compensation and its 2026 Equity Incentive Plan at the November 11, 2026 annual meeting. For fiscal 2026, revenue was $1.954 billion, up 9.3%, and adjusted earnings per share were $8.251, up 23.7%; both finished above the high end of guidance. Over the three-year Growth with Purpose strategy, enrollment rose from 76,000 to 100,000 students.
Covista returned $238 million to shareholders through repurchases at an average price of $98.35 per share, reducing shares outstanding by roughly 5%; the repurchases were funded from operating cash flow. It ended fiscal 2026 with $406 million of cash and net leverage of 0.5 times adjusted EBITDA. Its Purpose at Scale strategy targets 7%–10% revenue CAGR, 10%–14% adjusted EPS CAGR and more than 120,000 students through fiscal 2029; the company describes these as targets, not forecasts.
Covista Inc. repriced all $510 million of term loans outstanding immediately before the September 18, 2026 effective date. The Term SOFR margin changed from 2.25% to 2.00%; for base rate loans, the margin changed from 1.25% to 1.00%. These margins are added to the applicable benchmark rates.
Certain prepayments, repricings, or amendments qualifying as a Repricing Transaction are subject to a 1.00% premium if they occur on or before the date six months after the effective date. The amendment did not materially change the other terms and conditions, and the repriced loans otherwise retain the same material terms.
Covista Inc. (CVSA) reports that institutional investor FMR LLC has filed Amendment No. 2 to a Schedule 13G disclosing beneficial ownership of 3,553,635 shares of Covista common stock, representing 10.4% of the class as of August 31, 2026.
FMR LLC reports sole voting power over 3,553,007 shares and sole dispositive power over 3,553,635 shares. Abigail P. Johnson is also reported as having sole dispositive power over the same 3,553,635 shares, with no voting power.